Press Releases
GNS Healthcare and Scipher Medicine® Collaborate to Develop World’s First in silico Patient for Rheumatoid Arthritis
- Partnership leverages Scipher Medicine’s proprietary patient clinico-genomic data - In silico patient models enable pharmaceutical companies to understand what disease treatments work for which patients and why Somerville, Mass., and Waltham, Mass. ...
GNS Healthcare Announces a Multi-Year Collaboration with a Leading US Cancer Center to Advance Precision Medicine in Oncology
Collaboration with Memorial Sloan Kettering Cancer Center’s Innovation Hub aims to answer key questions in prostate cancer patient care and accelerate discovery and development of new treatments Somerville, Mass.– October 5, 2021– GNS Healthcare (GNS), an artificial...
GNS to Develop the World’s First in silico Patient For Prostate Cancer
Somerville, Mass., May 25, 2021: GNS Healthcare, an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, today announced plans to develop and launch Gemini — The in silico Patient™ for Prostate...
GNS to Develop the World’s First in silico Patient For Prostate Cancer
Somerville, Mass., May 25, 2021: GNS Healthcare, an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, today announced plans to develop and launch Gemini — The in silico Patient™ for Prostate...
GNS Healthcare Hires Alan Kilyk as Chief Financial Officer
Somerville, MA: GNS Healthcare, an AI company creating in silico patients to simulate disease progression and drug treatment at the individual patient level, is pleased to announce that accomplished finance executive Alan Kilyk has joined the company’s leadership team...
QIAGEN Adopts GNS Healthcare’s Gemini – The in silico Patient™ Across Multiple Cancers
Partnership enables enhanced capability to discover new targets and prognostic markers Somerville, MA: GNS Healthcare, the leading AI-driven precision medicine company, today announced a partnership with QIAGEN, the leading global provider of Sample to Insight...
GNS Healthcare Presents Novel Use of AI to Identify Drivers of Response to Immune Checkpoint Inhibitor Therapy
AI-driven in silico patients used to accurately identify types of immune responses in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). CAMBRIDGE, Mass.– [July 21, 2020] – GNS Healthcare (GNS), a leading AI and simulation company,...
GNS Healthcare Launches Gemini, the First In Silico Patient for Multiple Myeloma
A transformative innovation GeminiTM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma GNS Healthcare, an AI-driven precision medicine company, today announced the launch of...
GNS Healthcare Launches Gemini, the First In Silico Patient for Multiple Myeloma
A transformative innovation GeminiTM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma GNS Healthcare, an AI-driven precision medicine company, today announced the launch of...
GNS Healthcare and Multiple Myeloma Research Foundation (MMRF) Announce a Five-Year Collaboration to Advance Precision Medicine
Partnership Aims to Answer Key Questions in Multiple Myeloma Patient Care and Accelerate Discovery and Development of New Treatments Cambridge, MA – June 18, 2020-- GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) today announced a five-year...